Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for atrial fibrillation
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Regional Dominant Frequency: A New Tool for Wave Break Identification During AtrialFibrillation Cardiac mapping systems are based on the time/frequency feature analyses of intracardiac electrograms recorded from individual bipolar/unipolar electrodes. Signals from each electrode are processed independently. Such approaches fail to investigate the interrelationship between simultaneously recorded channels of any given mapping catheter during atrialfibrillation (AF). We introduce a novel signal (...) locations of AF or atrial tachycardia (ATach) termination and later compared offline with RDF and WBR maps. We inspected our novel metrics for associations with AF termination sites. Areas associated with AF termination demonstrated high RDF and low WBR (↑RDF,↓WBR). These sites were present in 14 of 15 patients (mean 2.6 ± 1.2 sites per patient; range, 1-4 sites), 43% situated within the pulmonary veins. In nine patients where AF terminated to sinus rhythm (6) or ATach (3), post-hoc analysis
Indexed Left Atrial Adipose Tissue Area Is Associated With Severity of AtrialFibrillation and AtrialFibrillation Recurrence Among Patients Undergoing Catheter Ablation Background: Epicardial adipose tissue (EAT) has been associated with adverse left atrial (LA) remodeling and atrialfibrillation (AF) outcomes, possibly because of paracrine signaling. Objectives: We examined factors associated with a novel measure of EAT i.e., indexed LAEAT (iLAEAT) and its prognostic significance after (...) catheter ablation (CA) of atrialfibrillation (AF). Methods: We performed a retrospective analysis of 274 participants with AF referred for CA. LAEAT area was measured from a single pre-ablation CT image and indexed to body surface area (BSA) to calculate iLAEAT. Clinical, echocardiographic data and 1-year AF recurrence rates after CA were compared across tertiles of iLAEAT. We performed logistic regression analysis adjusting for factors associated with AF to examine relations between iLAEAT and AF
CJEM Visual Abstract: Implementing an atrialfibrillation pathway CJEM Visual Abstract: Implementing an atrialfibrillation pathway - CanadiEM CJEM Visual Abstract: Implementing an atrialfibrillation pathway In by Alvin Chin June 8, 2018 In this issue, we collaborated with the CJEM team to create a visual abstract on the article: “Implementation of an emergency department atrialfibrillation and flutter pathway improves rates of appropriate anticoagulation, reduces length of stay and thirty (...) -day revisit rates for congestive heart failure.” 1 Atrialfibrillation and flutter are arrhythmias that come with significant morbidity and mortality 2 . Barbic et al. examined the effects of implementing an atrialfibrillation and flutter pathway on patient at two university-affiliated urban sites. 1 Their primary outcome was the proportion of patients who were correctly started on new anticoagulant medications by the treating emergency physician over an eight month period. The results
Treatment of AtrialFibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines? AF in patients with heart failure and reduced ejection fraction (HFrEF) is common and is associated with an increased risk of stroke, heart failure hospitalisation and all-cause mortality. Rhythm control of AF in this population has been traditionally limited to the use of antiarrhythmic drugs. Clinical trials assessing superiority
AtrialFibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All Atrialfibrillation (AF) is common in patients with heart failure and is associated with poorer clinical outcomes compared with patients with heart failure alone. Recent evidence has challenged previous treatment paradigms in which rate control was considered equivalent to rhythm control in this population. Catheter ablation has emerged as a safe and effective treatment strategy in selected patients
Risk Factor Management in AtrialFibrillationAtrialfibrillation (AF) is the most common clinical arrhythmia and is associated with increased morbidity and mortality. There is growing evidence that numerous cardiovascular diseases and risk factors are associated with incident AF and that lone AF is rare. Beyond oral anticoagulant therapy, rate and rhythm control, therapy targeting risk factors and underlying conditions is an emerging AF management strategy that warrants better implementation
Association of Burden of AtrialFibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal AtrialFibrillation: The KP-RHYTHM Study Atrialfibrillation is a potent risk factor for stroke, but whether the burden of atrialfibrillation in patients with paroxysmal atrialfibrillation independently influences the risk of thromboembolism remains controversial.To determine if the burden of atrialfibrillation characterized using noninvasive, continuous ambulatory monitoring is associated (...) with the risk of ischemic stroke or arterial thromboembolism in adults with paroxysmal atrial fibrillation.This retrospective cohort study conducted from October 2011 and October 2016 at 2 large integrated health care delivery systems used an extended continuous cardiac monitoring system to identify adults who were found to have paroxysmal atrialfibrillation on 14-day continuous ambulatory electrocardiographic monitoring.The burden of atrialfibrillation was defined as the percentage of analyzable wear
Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrialfibrillation: retrospective cohort studies. To determine rates of stroke or transient ischaemic attack (TIA) and all cause mortality in patients with a diagnosis of "resolved" atrialfibrillation compared to patients with unresolved atrialfibrillation and without atrial fibrillation.Two retrospective cohort studies.General practices contributing to The Health Improvement Network, 1 January 2000 to 15 (...) May 2016.Adults aged 18 years or more with no previous stroke or TIA: 11 159 with resolved atrialfibrillation, 15 059 controls with atrialfibrillation, and 22 266 controls without atrial fibrillation.Primary outcome was incidence of stroke or TIA. Secondary outcome was all cause mortality.Adjusted incidence rate ratios for stroke or TIA in patients with resolved atrialfibrillation were 0.76 (95% confidence interval 0.67 to 0.85, P<0.001) versus controls with atrialfibrillation and 1.63 (1.46
Lifestyle Therapy for the Management of AtrialFibrillationAtrialfibrillation (AF) is a common arrhythmia associated with increased risk of morbidity and mortality. There is evidence that lifestyle interventions may serve as complementary treatments to reduce AF burden. The objective of this review was to summarize the efficacy of lifestyle interventions for the management of AF. Studies which included patients with systolic heart failure (ejection fraction ≤40%), and those limited
A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrialfibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting (the CDS-AF study) Atrialfibrillation (AF) is associated with substantial morbidity, in particular stroke. Despite good evidence for the reduction of stroke risk with anticoagulant therapy, there remains significant undertreatment. The main aim of the current study was to investigate
Apixaban compared to heparin/vitamin K antagonist in patients with atrialfibrillation scheduled for cardioversion: the EMANATE trial The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrialfibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion.One thousand five hundred patients were randomized. The apixaban dose of 5 mg b.i.d. was reduced to 2.5 mg b.i.d. in patients with two of the following: age ≥ 80
Incident Risk Factors and Major Bleeding in Patients with AtrialFibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors When assessing bleeding risk in patients with atrialfibrillation (AF), risk stratification is often based on the baseline risks. We aimed to investigate changes in bleeding risk factors and alterations in the HAS-BLED score in AF patients. We hypothesized
Atrialfibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study Essentials Atrialfibrillation (AF) may increase risk of venous thromboembolism (VTE), and vice versa. Bidirectionality was assessed prospectively via data from 15 129 black and white individuals. AF was associated with greater risk of developing VTE, and VTE with greater risk of AF. Associations were strongest among blacks and in the first 6 months after initial (...) diagnosis.Background Atrialfibrillation (AF) and venous thromboembolism (VTE) frequently co-occur. These conditions have shared risk factors and are accompanied by coagulation abnormalities. Furthermore, mechanistic pathways may directly link the disorders. Objectives To test the hypothesis that individuals with incident AF are at greater risk of developing VTE, and those with VTE are at elevated risk of AF. We also tested whether associations were stronger in the first 6 months after the initial diagnosis
Selective screening for atrialfibrillation using multivariable risk models Atrialfibrillation can lead to stroke if untreated, and identifying those at higher risk is necessary for cost-effective screening for asymptomatic, paroxysmal atrialfibrillation. Age has been proposed to identify those at risk, but risk models may provide better discrimination. This study compares atrialfibrillation risk models with age for screening for atrial fibrillation.Nine atrialfibrillation risk models were (...) compared using the Atherosclerosis Risk in Communities study (11 373 subjects, 60.0±5.7 years old). A new risk model (Screening for Asymptomatic AtrialFibrillation Events-SAAFE) was created using data collected in the Monitoring Disparities in Chronic Conditions study (3790 subjects, 58.9±15.3 years old). The primary measure was the fraction of incident atrialfibrillation subjects who should receive treatment due to a high CHA2DS2-VASc score identified when screening a fixed number equivalent
Lifetime risk of atrialfibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. To examine the association between risk factor burdens-categorized as optimal, borderline, or elevated-and the lifetime risk of atrial fibrillation.Community based cohort study.Longitudinal data from the Framingham Heart Study.Individuals free of atrialfibrillation at index ages 55, 65, and 75 years were assessed (...) . Smoking, alcohol consumption, body mass index, blood pressure, diabetes, and history of heart failure or myocardial infarction were assessed as being optimal (that is, all risk factors were optimal), borderline (presence of borderline risk factors and absence of any elevated risk factor), or elevated (presence of at least one elevated risk factor) at index age.Lifetime risk of atrialfibrillation at index age up to 95 years, accounting for the competing risk of death.At index age 55 years, the study
Association between incidence of atrialfibrillation and duration of cardiopulmonary bypass in coronary artery bypass graft surgery (CABG): a cohort study Open heart surgery is one of the most common and valuable treatment methods for cardiovascular diseases, a common side effect of which is atrialfibrillation that occurs due to various reasons.To determine the relationship between incidence of atrialfibrillation (AF) and duration of cardiopulmonary bypass (CPB) in patients after open heart (...) of the patients was 61.76±9.2, the majority of the patients (70.1%) were male. The association between Incidence of AtrialFibrillation and cardiopulmonary pump time (minute) was not meaningful. Incidence of atrialfibrillation had statistically significant relationship with variables of mean age, BMI, PAC, PVC, creatinine and duration of hospitalization (p<0.05); on the other hand, variables of gender, cross clamp time (minute), intubation time (hour), and clinical history had no effect on atrial
Digoxin and Mortality in Patients With AtrialFibrillation Digoxin is widely used in patients with atrialfibrillation (AF).The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modified by heart failure and/or serum digoxin concentration.The association between digoxin use and mortality was assessed in 17,897 patients by using a propensity score-adjusted analysis and in new digoxin users
Apixaban in patients at risk of stroke undergoing atrialfibrillation ablation It is recommended to perform atrialfibrillation ablation with continuous anticoagulation. Continuous apixaban has not been tested.We compared continuous apixaban (5 mg b.i.d.) to vitamin K antagonists (VKA, international normalized ratio 2-3) in atrialfibrillation patients at risk of stroke a prospective, open, multi-centre study with blinded outcome assessment. Primary outcome was a composite of death, stroke (...) , or bleeding (Bleeding Academic Research Consortium 2-5). A high-resolution brain magnetic resonance imaging (MRI) sub-study quantified acute brain lesions. Cognitive function was assessed by Montreal Cognitive Assessment (MoCA) at baseline and at end of follow-up. Overall, 674 patients (median age 64 years, 33% female, 42% non-paroxysmal atrialfibrillation, 49 sites) were randomized; 633 received study drug and underwent ablation; 335 undertook MRI (25 sites, 323 analysable scans). The primary outcome